Brandyn Tarap, MD
Family Medicine · Custer, SDNPI 1619316585
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$641
- AstraZeneca$449
- Lilly USA, LLC$360
- Bayer$212
- Novo Nordisk$211
- Boehringer Ingelheim$206
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,34197%
- Education$1123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 38 | $641 |
| AstraZeneca | 18 | $449 |
| Lilly USA, LLC | 23 | $360 |
| Bayer | 7 | $212 |
| Novo Nordisk | 14 | $211 |
| Boehringer Ingelheim | 14 | $206 |
| Novartis | 11 | $198 |
| Pfizer | 12 | $197 |
| AbbVie | 7 | $168 |
| Exact Sciences | 9 | $159 |
| E.r. Squibb & Sons, L.L.C. | 6 | $116 |
| GSK | 8 | $112 |
| Actelion Pharmaceuticals US, Inc. | 1 | $100 |
| Merck | 5 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $75 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Johnson & Johnson | 2 | $31 |
| Nobel Biocare USA | 1 | $28 |
| Abiomed | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,453 in reported general payments places this provider in the 90th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 80 | $67,460 |
| MounjaroTirzepatide | 47 | $61,141 |
| EliquisApixaban | 69 | $51,152 |
| XareltoRivaroxaban | 33 | $40,662 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $24,927 |
| FarxigaDapagliflozin Propanediol | 41 | $24,846 |
| RybelsusSemaglutide | 18 | $17,712 |
| JanuviaSitagliptin Phosphate | 12 | $11,098 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $10,328 |
| OzempicSemaglutide | 11 | $10,147 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 44 | $9,909 |
| EntrestoSacubitril/Valsartan | 15 | $9,834 |
| KerendiaFinerenone | 13 | $8,273 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,637 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $206 | $67,46080 claims |
| Lilly USA, LLCMounjaro | $360 | $61,14147 claims |
| PfizerEliquis, Premarin | $197 | $53,62781 claims |
| Johnson & JohnsonXarelto | $31 | $40,66233 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $112 | $39,47390 claims |
| AstraZenecaFarxiga, Symbicort | $449 | $29,16453 claims |
| Novo NordiskRybelsus, Ozempic | $211 | $27,85929 claims |
| MerckJanuvia | $80 | $11,09812 claims |
| NovartisEntresto | $198 | $9,83415 claims |
| BayerKerendia | $212 | $8,27313 claims |
| AbbVieSynthroid | $168 | $1,90135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Custer
- Terry GraberCuster$6K
- Joy FalkenburgCuster$3K
- Monaleze SainiCuster$2K
- Lisa BrownCuster$2K
- Louise HalbleibCuster$1K
- Kyla Helm-SwansonRapid City$22K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.